EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment for inflammatory bowel disease with a vcam-1/1gG fusion protein



Treatment for inflammatory bowel disease with a vcam-1/1gG fusion protein



Official Gazette of the United States Patent & Trademark Office Patents 1264(3), Nov 19



A method for the treatment of inflammatory bowel disease (IBD) is disclosed. The method comprises administration of a VCAM-1/IgG fusion protein.

(PDF 0-2 workdays service: $29.90)

Accession: 035980217

Download citation: RISBibTeXText



Related references

Elevation of soluble VCAM-1 in the serum of patients with inflammatory bowel disease. Gastroenterology 106(4 SUPPL ): A689, 1994

Elevated ICAM-1, VCAM-1 and E-selectin in active inflammatory bowel disease. Gastroenterology 106(4 SUPPL ): A690, 1994

Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction: amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand-IgG fusion protein. Journal of Immunology 162(1): 486-493, 1999

Recent advances in basic and clinical aspects of inflammatory bowel disease: which steps in the mucosal inflammation should we block for the treatment of inflammatory bowel disease?. World Journal of Gastroenterology 13(15): 2145-2149, 2007

ICAM-1 and VCAM-1 antisense oligonucleotides attenuate in vivo leucocyte adherence and inflammation in rat inflammatory bowel disease. Gut 51(4): 529-535, 2002

ICAM-1 and VCAM-1 antisense oligonucleotides attenuate leukocyte adhesion and inflammation in a rat model of inflammatory bowel disease. Gastroenterology 118(4 Suppl 2 Part 1): AGA A577, April, 2000

Open-label, uncontrolled trial of bowel sterilization and repopulation with normal bowel flora for treatment of inflammatory bowel disease. Current Therapeutic Research. 58(12): 1001-1012,., 1997

Overexpression of translocator protein in inflammatory bowel disease: potential diagnostic and treatment value. Inflammatory Bowel Diseases 16(9): 1476-1487, 2010

Increased Cell Adhesion Molecules, PECAM-1, ICAM-3, or VCAM-1, Predict Increased Risk for Flare in Patients With Quiescent Inflammatory Bowel Disease. Journal of Clinical Gastroenterology (): -, 2016

Surgical treatment of inflammatory bowel diseases in northwestern Italy: a multicentric study by the G.S.M.I.I. (Inflammatory Bowel Disease Study Group). Annali Italiani di Chirurgia 74(3): 319-326, 2003

Disease outcome in inflammatory bowel disease: Mortality, morbidity and therapeutic management of a 796-person inception cohort in the European collaborative study on inflammatory bowel disease (EC-IBD). Scandinavian Journal of Gastroenterology 35(12): 1272-1277, 2000

Disease outcome in inflammatory bowel disease: mortality, morbidity and therapeutic management of a 796-person inception cohort in the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Scandinavian Journal of Gastroenterology 35(12): 1272-1277, 2001

De novo Crohn's Disease after Ileal Pouch-Anal Anastomosis for Ulcerative Colitis and Inflammatory Bowel Disease Unclassified: Long-Term Follow-Up of a Prospective Inflammatory Bowel Disease Registry. American Surgeon 82(10): 977-981, 2016

Macrophage inflammatory protein -3alpha expression is increased in human inflammatory bowel disease Role in Crohns disease. Journal of Investigative Dermatology 117(4): 1018, October, 2001